COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
Remdesivir study #9 of 16
10/8 Late treatment study
Beigel et al., NEJM, doi:10.1056/NEJMoa2007764 (Peer Reviewed)
Remdesivir for the Treatment of Covid-19 — Final Report
Source   PDF   Share   Tweet
RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29, p<0.001.
Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio HR 0.73 [0.52-1.03].

Beigel et al., 10/8/2020, Randomized Controlled Trial, USA, multiple countries, North America, multiple regions, peer-reviewed, 12 authors.
risk of death, 27.0% lower, RR 0.73, p = 0.07, treatment 541, control 521.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 16 studies
Please send us corrections, updates, or comments.
Submit